Dr. Lisa Rider is a Pediatric Rheumatologist and Head of the Environmental Autoimmunity Group, National Institute of Environmental Health Science, National Institutes of Health, in Bethesda, Maryland, USA.
Dr. Rider received her BA and MD degrees from Duke University. After completing her pediatrics residency and a clinical fellowship in pediatric rheumatology at the University of Washington/Seattle Children’s Hospital, she became a Research Associate in NIAMS, National Institutes of Health. She then joined Dr. Frederick Miller’s laboratory at the Center for Biologics, Food and Drug Administration, and later became Deputy Chief of the group, which moved to NIEHS in 2002.
Since 2008, Dr. Rider has also been Clinical Professor of Medicine at George Washington University, where she sees patients and leads research on juvenile myositis in the Cure JM Center for Excellence.
Dr. Rider’s research has focused on juvenile myositis, in which her work helped define the major autoantibody phenotypes and their associated outcomes, and identified genetic and environmental risk factors for myositis in children. She has led the international development of validated outcome measures and clinical trial response criteria, and co-led clinical trials of new therapies for juvenile myositis. Dr. Rider has been the co-founder and co-lead of the International Myositis Assessment and Clinical Studies (IMACS) Group, an international consortium of myositis researchers.
She has co-authored more than 170 peer-reviewed publications, 45 book chapters and review articles, and was the lead editor of a book published by Cure JM, Myositis and You.
She has received several awards in recognition of her contributions, including Physician Researcher of the Year by the US Public Health Service (2011), the 2017 Cure JM Lifetime Achievement in Research award, The Myositis Association’s 25th Anniversary Research Award: For Outstanding Contributions to Myositis Research, and the Excellence in Investigative Mentoring Award from the American College of Rheumatology (2022).